Quick Answer
IN8BIO, INC. reported R&D Expense of $10.21 million for fiscal year 2025.
IN8BIO, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.21M | -39.8% |
| 2024 | $16.96M | +0.8% |
| 2023 | $16.83M | +19.7% |
| 2022 | $14.06M | +91.4% |
| 2021 | $7.35M | +36.6% |
| 2020 | $5.38M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.10M | -36.4% | -15.4% |
| June 30, 2025 | $2.49M | -51.8% | -16.3% |
| March 31, 2025 | $2.97M | -39.4% | -10.2% |
| September 30, 2024 | $3.31M | -12.6% | -35.8% |
| June 30, 2024 | $5.16M | +24.7% | +5.2% |
| March 31, 2024 | $4.90M | +11.8% | +29.5% |
| September 30, 2023 | $3.79M | -11.0% | -8.4% |
| June 30, 2023 | $4.13M | +18.0% | -5.7% |
- IN8BIO, INC. showed a decrease of -39.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, IN8BIO, INC.’s r&d expense has grown by 89.9% (from $5.38 million to $10.21 million).
- The most recent figure is from IN8BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: